The maker of ChloraPrep®, Medi-Flex, Inc., will begin operating as Enturia, Inc. effective Jan. 15, 2007. Aime Lenz, senior product manager, comments, Our company vision is about growth, innovation and improving healthcare. To achieve this vision, we are introducing new products, broadening our preventative scope, and expanding into international markets. We recognize that to be successful our strategy must begin at a fundamental levelwith our corporate identity and company name. Lenz adds that the company will also introduce a commitment to basically better health.
According to Lenz in a letter sent to customers, The name Enturia is inspired by three ideas centurion (signifying our commitment to providing protection from illness); venture (signifying our commitment to innovation); and endurance (signifying our commitment to the cause of basically better health). These ideas have developed over the last 21 years, and are a reflection of our dedication to retaining our core personality and values of delivering against our mission of basically better health. Lenz adds, We believe that good health is the cornerstone of human happiness. We see medicine as a human science and our role is to combine the clinical science with human understanding. These values involve combining competence with caring, while focusing on practitioner needs. Enturia, Inc. is a new name but at our core we remain the same company we have been for over 20 years. As Enturia moves into an exciting and promising future, we look forward to our continued partnership.
Source: Enturia, Inc.
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.